nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

19.10.2016 | Letter to the Editor

Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? – Wait for confirmation study

Reply to Jorgov et al. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220--30

verfasst von: Regine Kluge, Lars Kurch, Thomas Georgi, Dirk Hasenclever

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, et al. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1220–30.

Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69(6):979–85.CrossRefPubMedPubMedCentral

Lausen B, Schumacher M. Evaluating the effect of optimized cutoff values in the assessment of prognostic factors. Computational Statistics & Data Analysis. 1996;21(3):307–26.CrossRef

Titel: Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? – Wait for confirmation study
Reply to Jorgov et al. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220--30
verfasst von: Regine Kluge
Lars Kurch
Thomas Georgi
Dirk Hasenclever
Publikationsdatum: 19.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3534-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

Reply to Rahbar K et al.

Editorial: Listen to your belly, fat is not your foe!

Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience

EANM Springer Prizes awarded at EANM’ 16 Barcelona

Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma